Zobrazeno 1 - 10
of 26
pro vyhledávání: '"R A Vere Hodge"'
Autor:
Aruna Sampath, R. Anthony Vere Hodge, Kara Carter, E. Bart Tarbet, Zlatko Janeba, José A. Esté, Mike Bray, Luis M. Schang, Graciela Andrei
Publikováno v:
Antiviral Research
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname
The 30th International Conference on Antiviral Research (ICAR) was held in Atlanta, GA, USA from May 18 to 21, 2017. This report provides an account of award lectures, invited keynote addresses and oral presentations during the meeting. The 2017 Gert
Autor:
R. Anthony Vere Hodge
Publikováno v:
Antiviral Research
Highlights • This article summarizes the principal invited lectures at the 28th International Conference on Antiviral Research. • Phillip Furman, Elion award recipient, described research leading to the discovery of sofosbuvir. • Dennis Liotta,
Autor:
R. Anthony Vere Hodge
Publikováno v:
Antiviral Research
Highlights • The 27th ICAR was held in Raleigh, NC, USA, May 12–16, 2014. This article summarizes the principal invited lectures. • The Elion Award lecturer recalled the early days of antiviral drugs and how their modes of action were elucidate
Autor:
R. Anthony Vere Hodge
Publikováno v:
Antiviral Research
Highlights • The 26th International Conference on Antiviral Research was held in San Francisco from May 11 to 15, 2013. • The opening symposium paid tribute to the work of the late Antonín Holý. • The Gertrude Elion Award lecturer described t
Autor:
R Anthony, Vere Hodge, Hugh J, Field
Publikováno v:
Advances in pharmacology (San Diego, Calif.). 67
This review starts with a brief description of herpes simplex virus types 1 and 2 (HSV-1 and HSV-2), the clinical diseases they cause, and the continuing clinical need for antiviral chemotherapy. A historical overview describes the progress from the
Autor:
Hugh J. Field, R Anthony Vere Hodge
Publikováno v:
British medical bulletin. 106
Background Herpesviruses notably establish lifelong infections, with latency and reactivation. Many of the known human herpesviruses infect large proportions of the population worldwide. Treatment or prevention of herpes infections and recurrent dise
Autor:
R. A. Vere Hodge, Yung-Chi Cheng
Publikováno v:
Antiviral Chemistry and Chemotherapy. 4:13-24
This review describes the studies that have been carried out to date to investigate the mode of action of penciclovir. Penciclovir is phosphorylated much more efficiently than acyclovir in herpesvirus-infected cells yet the host cell kinases phosphor
Autor:
R. A. Vere Hodge
Publikováno v:
Antiviral Chemistry and Chemotherapy. 4:67-84
Famciclovir is the oral form of penciclovir, a highly selective antiherpesvirus agent. Both famciclovir and penciclovir are being evaluated in clinical studies. This review covers the conversion of famciclovir to penciclovir, the formation and stabil
Publikováno v:
Chirality. 5:577-582
Famciclovir is the oral form of the potent antiherpesvirus agent, penciclovir. Hydrolysis of one of the acetyl ester groups of famciclovir creates a chiral centre leading to the possible formation of (R)- and (S)-enantiomers. During its conversion to
Autor:
R Anthony Vere, Hodge
Publikováno v:
Current opinion in investigational drugs (London, England : 2000). 5(2)
Idenix (formerly Novirio) and Novartis are developing two beta-L-deoxynucleosides, telbivudine and torcitabine, for the potential treatment of hepatitis B virus infection. Phase III trials of telbivudine were underway by August 2002 and phase I/II tr